Cranberry Extract has been shown to be better for the prevention of urinary tract infection (UTI), and clinical trials have shown that 36mg daily of procyanidins (PACs) reduced UTI recurrence by 35% in women (RR=0.65, 95%CI 0.48-0.88). A 2020 randomized controlled trial in the American Journal of Clinical Nutrition found that 6-month supplementation with Cranberry Extract (50mg/ dose PACs content) reduced the incidence of UTI by 40% with placebo, and the efficacy was better than with trimethopillin antibiotics (28% decrease). Urell® with 72mg PACs of Pharmatoka, a drug company, was certified as a Class Ⅱa medical device in the European Union with an 80% efficiency of anti-bacterial adhesion (in vitro model test).
For cardiovascular health, Cranberry Extract reduced systolic blood pressure by 5.2mmHg on average (p=0.004) in patients with hypertension through a 9.8% increase in HDL-C (high density lipoprotein cholesterol) and a 43% reduction in LDL oxidation rate (ORAC value 3200μmol TE/g). A 240ml per day dose of Cranberry juice that had 27% Cranberry Extract was efficacious in the U.S. Department of Agriculture trial for 8 weeks by raising arterial stiffness index (CAVI) 12% (compared with 3% in controls) and vascular endothelial function index (FMD) 2.1 percentage points.
Cranberry Extract antioxidant and anti-inflammatory properties were highlighted. IC50 value of free radical clearance DPPH was 32μg/mL (vitamin C was 45μg/mL), and activity of COX-2 enzyme was inhibited by 78% (concentration was 100μg/mL). In osteoarthritis model, a formulation with Cranberry Extract (150mg/kg daily) reduced synovial IL-1β by 62% (55% in diclofenac) and cartilage degradation area by 47%. In 2022, Italian scientists demonstrated that its polyphenol fraction inhibited NF-κB pathway activation (inhibition rate IC50=28μM) and lowered CRP (C-reactive protein) levels by 41% (p<0.01).
In mouthwashes, Cranberry Extract at 1.5% in oral hygiene prevented 54% (63% in the chlorhexidine group) of plaque biofilm formation and was less toxic to oral symbiotic flora (pathogen inhibition specificity up to 89%). In a double-blind randomized trial, 4-week repeated use of toothpaste with this ingredient reduced gum bleeding index by 43% (22% reduction in control toothpaste) and Streptococcus mutans concentration by 1.7log CFU/mL (p=0.002).
The gastoprotective activity of Cranberry Extract was impressive. Cranberry Extract inhibited the urease activity of Helicobacter pylori (IC50=85μg/mL) and reduced gastric mucosa damage by 68% in the infected model (51% in omeprazole treatment). Human clinical trials proved that 500mg daily of the standardized extract increased the intestinal bifidobacteria number by 2.3 times (qPCR), while reducing fecal calvetin levels (a biomarker of inflammation) by 39% (p=0.03).
Topically applied 5% Cranberry Extract increased dermal collagen density by 35% in UV-induced photoaging mouse models via 77% inhibition of MMP-1 (collagenase) activity (82% inhibition in retinol treatment group). French ingredient company Indena’s Cranberol® (6% proanthocyanidins A) has been reported to reduce transepidermal water loss (TEWL) by 22% and recover barriers 1.8 times faster than control.
In terms of metabolic control, Cranberry Extract (450mg daily) therapy for 12 weeks can reduce fasting insulin level by 18% (27% improvement in HOMA-IR index) and visceral fat area by 6.3cm² (MRI detection) in obese subjects. Its flavonol component can activate AMPK pathway (the phosphorylation level is increased by 3.1-fold) and increase mitochondrial biosynthesis in adipocytes (PPARγcoactivator-1α mRNA expression +240%).
Safety data provide ample application scope, Cranberry Extract having been registered as a food additive by the European Union EFSA (every day allowable dose of 300mg PACs/kg body weight) and with 90-day subchronic toxicities inducing no liver and kidney damage (ALT/AST, BUN/Cr values fluctuating < 15%). The global market size will be $620 million in 2023 (Frost & Sullivan estimates), while the functional foods and dietary supplements market penetration rate will increase by 9.8% per annum, thus justifying its multi-dimensional health worth.